Vyome Holdings, Inc.

What they do

The company operates in two segments: biotechnology, which comprises its VT-1953, VT-1908 and VB-1953 development programs, and pharmaceutical products, which comprises reformulated topical antifungals commercialized in India under agreements with Sun Pharma Laboratories Limited. No biotechnology product is approved for sale and the company reports no product revenue from that segment. The pharmaceutical segment represents a legacy business and licensing arrangements with Sun Pharma.

Revenue drivers

• Pharmaceutical products (antifungals) — The company receives a net service fee from Sun Pharma on sales of reformulated MRT-based antifungal products in India; under a 2023 amendment it no longer purchases or sells the inventory itself.
• Luliconazole topical cream licensing — An agreement with Sun Pharma covers development and licensing of an MRT technology-based Luliconazole topical cream for skin fungal diseases in India, commercialized by Sun Pharma in 2023.
• Biotechnology segment — VT-1953, VT-1908 and VB-1953 remain in development; the company states it has not generated any revenue from product sales in this segment.

Recent performance

For the quarter ended June 30, 2026, revenue was about $26,955 and total operating expenses were approximately $874,000, including $507,000 of R&D and $365,000 of SG&A. Net loss attributable to common shareholders was approximately $720,000, or about $0.10 per basic and diluted share. Cash and cash equivalents were approximately $7.9 million at June 30, 2026, versus $5.0 million at December 31, 2025. Total assets were $9.2 million and total stockholders' equity $7.3 million at June 30, 2026. Full-year 2025 net loss was $10.3 million, and 2024 net loss was $1.4 million.

Strategy

The company's stated priority is its lead program VT-1953 topical gel for signs and symptoms of malignant fungating wounds, for which it filed an Orphan Drug Designation application in January 2026 and submitted a pre-IND briefing package to the FDA in March 2026. After receiving the FDA's written response during the second quarter of 2026, it is incorporating the feedback and plans a Type C meeting before advancing pivotal development. It is also selectively expanding around immuno-inflammatory disease, including a May 2026 in-licensing agreement with Impetis Biosciences for two preclinical selective JAK inhibitor assets carrying no upfront, development funding or milestone obligations, only a 1.5% royalty on future net sales. Management emphasizes a clean capital structure with no debt, no preferred stock and no toxic financing instruments.

Risks

• No approved products; no biotechnology revenue — The company states it has no products approved for sale and has not generated any revenue from product sales from its biotechnology segment, and its risk factors say it may never generate revenue or become profitable.
• History of losses — The company has incurred losses since inception and expects significant losses for the foreseeable future, with annual net losses of $63.1 million (2021), $46.2 million (2022), $11.4 million (2023), $1.4 million (2024) and $10.3 million (2025).
• Clinical and regulatory delay — The company notes trials can be delayed by regulatory approval to commence, site and IRB agreements, patient recruitment or supply of trial materials, and its pivotal VT-1953 program still requires FDA engagement through a Type C meeting.
• Dependence on Sun Pharma arrangements — Its pharmaceutical segment revenue derives from licensing and marketing arrangements with Sun Pharma, one dandruff supply agreement was terminated in December 2024, and the shampoo agreement terminated in 2024.

Outlook

Management says VT-1953 remains its lead priority and that it will continue engagement with the FDA, including through a Type C meeting, before advancing the pivotal clinical development program. It intends to advance the two in-licensed Impetis JAK inhibitor assets in a disciplined manner using non-dilutive methods while keeping VT-1953 primary. The company also states it maintains a clean capital structure with no debt, no preferred stock and no toxic financing instruments.